FOXO4-DRI
An experimental "senolytic" peptide designed to clear senescent (aged, non-dividing) cells. A single influential mouse study generated interest in it for ageing, but there is no human data at all, and it should be treated as purely preclinical.
Quick take
- What it is: an experimental peptide designed to selectively trigger the death of senescent ("zombie") cells that accumulate with age.
- What people use it for: anti-ageing and longevity — entirely as an experimental, research-driven idea.
- What we actually know: the main evidence is a single notable mouse study; there are no human studies, so its effects and safety in people are unknown.
- Status: experimental and not approved anywhere; sold only as an unapproved research peptide.
What it is
FOXO4-DRI is an experimental “senolytic” peptide — a molecule designed to selectively eliminate senescent cells. Senescent cells are aged cells that have stopped dividing but do not die; instead they accumulate with age and release inflammatory signals thought to contribute to ageing and age-related disease. The “DRI” refers to a D-retro-inverso design that makes the peptide more stable.1
It rose to prominence after a single, widely publicised mouse study. The most important thing to understand is that its reputation rests on preclinical research only.
How it works
Many senescent cells survive by relying on interactions between the proteins FOXO4 and p53. FOXO4-DRI is designed to disrupt that interaction, freeing p53 to trigger programmed cell death (apoptosis) preferentially in senescent cells while sparing healthy ones.2 The hope is that selectively clearing these cells could reduce age-related dysfunction.
This is an elegant mechanism in principle, but it targets a core cell-survival pathway, and its selectivity and safety in a living human body are unproven.
What the evidence shows
Laboratory and animal studies
The key evidence is a 2017 mouse study (and supporting cell work) reporting that FOXO4-DRI could selectively kill senescent cells and improve several markers of ageing in mice — including measures of fitness, fur density and kidney function.2 This result drove substantial interest in senolytics generally.
Human studies
There are no human studies of FOXO4-DRI. No human dosing, efficacy or safety has been established. The honest summary is a single striking mouse result and nothing in people — a very long way from a validated anti-ageing therapy.
Dosages reported in the literature
Informational only. There is no validated human dosing for FOXO4-DRI. The note below reflects only the research context. It is not a recommendation or a prescription.
| Setting | Route | Reported range |
|---|---|---|
| Laboratory / mouse research | Injection | Experimental only; not applicable to humans |
| Human use | — | No established dosing exists |
Because there are no human trials, there is no dose range that can be considered safe or effective for people.
Safety & side effects
There are no human safety data for FOXO4-DRI. Because it works by triggering cell death through the p53 pathway, off-target or excessive effects are a genuine theoretical concern, and its real risk profile in people is entirely unknown.
As an experimental research chemical, any material sold as “FOXO4-DRI” also carries serious concerns about identity, purity and dose accuracy.
Legal & regulatory status
FOXO4-DRI is not approved by the FDA or any other regulator for any use. It is an experimental compound sold only as an unapproved research peptide.3 Rules differ by country and change over time.
References
- Bourgeois B, Madl T. Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Letters. 2018;592(12):2083-2097. [PMID 29683489, doi:10.1002/1873-3468.13057]
- Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. [PMID 28340339, doi:10.1016/j.cell.2017.02.031]
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA Human Drug Compounding. [fda.gov] (source identified; pending manual verification)